Safety of biologic therapies - An update

Journal of Rheumatology

Volumn 32, Issue SUPPL. 74, 2005, Pages 8-12

  Keystone, Edward C ^a,b,c,d  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d Division of Advanced Therapeutics   (Canada)

Author keywords

Biologic therapies; Clinical trials; Rheumatoid arthritis; Safety

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; METHOTREXATE; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ASPERGILLOSIS; CANCER; CANCER INCIDENCE; CLINICAL TRIAL; COCCIDIOIDOMYCOSIS; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; CROHN DISEASE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG SAFETY; EXTRAPULMONARY TUBERCULOSIS; HISTOPLASMOSIS; HODGKIN DISEASE; HUMAN; IMMUNOMODULATION; INCIDENCE; INFECTION RISK; LISTERIOSIS; LYMPHOMA; MALIGNANT TRANSFORMATION; MILIARY TUBERCULOSIS; MORTALITY; MYCOBACTERIUM TUBERCULOSIS; NONHODGKIN LYMPHOMA; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS PNEUMONIA; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SOCIAL CLASS; TUBERCULOSIS; TUBERCULOUS LYMPHADENITIS; TUBERCULOUS PLEURISY; DRUG ANTAGONISM; DRUG SURVEILLANCE PROGRAM; IMMUNE DEFICIENCY; REVIEW;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOGLOBULIN G; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 20144367312     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (26)

1. Keystone EC. Advances in targeted therapy: safety of biological agents. Ann Rheum Dis 2003;62 Suppl 2:34-6.
2. Scott H, Rosenbaum S, Waters W. et al. Rhode Island physicians recognition and reporting of adverse drug reactions. RI Med J 1987;70:311-6.
3. Rawlins MD. Pharmacovigilance: paradise lost, regained or postponed. J R Coll Physicians Lond 1995;29:41-9.
4. Martin RM, Kapoor KV, Wilton LV, et al. Underreporting of suspected adverse drug reactions to newly marketed ("black triangle") drugs in general practice: observational study. BMJ 1998;317:119-20.
5. Heeley E, Riley J, Layton D, et al. Prescription event monitoring and reporting of adverse drug reactions. Lancet 2001;358:1872-3.
6. ten Hove T, van Montfrans C, Peppelenbosch MP, et al. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 2002;50:206-11.
7. Lugering A, Schmidt M, Lugering N, et al. Infliximab induces apoptosis in monocytes from patients with Crohn's disease by using a caspase-dependent pathway. Gastroenterology 2001;121:1145-57.
8. van den Brande JMHV Braat H, van den Brink GR, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003;124:1774-85.
9. Catrina AI, Trollmo C, AfKlint, et al. Evidence that anti-tumor necrosis factor therapy with both entanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: Extended report. Arthritis Rheum 2005;52:61-72.
10. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD, BIOBADASER group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant, increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003;48:2085-91.
11. Wolfe F, Michaud K, Anderson J, et al. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004;50:372-9.
12. Emery P, Panayi G, Symmons D, et al. Mechanisms of depressed delayed-type hypersensitivity in rheumatoid arthritis: the role of protein energy malnutrition. Ann Rheum Dis 1984;43:430-4.
13. Bergstrom L, Yocum DE, Ampel NM, et al. Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists. Arthritis Rheum 2004;50:1959-66.
14. Anker SD, Coates AJ. How to recover from renaissance? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH 2002. Int J Cardiol 2002;86:123-30.
15. Coletta AP, Clark AL, Banarjee, Cleland JG. Clinical trials update: RENEWAL, (RENAISSANCE RECOVER) and ATTACH. Eur J Heart Fail 2002;4:559-61.
16. Chung ES, Packer M, Lokh, Fascenmade AA, Willerson JT; Anti-TNF Therapy Against Congestive Heart Failure Investigators. Randomized double-blind, placebo-controlled pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate to severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003;107:3133-40.
17. Wolfe F, Michaud MS. Congestive heart failure in rheumatoid arthritis: rates, predictors and the effect of anti-TNF therapy. Am J Med 2004;116:305-11.
18. Gonzalez-Juanatey C, Testa A, Garcia-Castelo A, Llocca J, Gonzalez-Gay MA. Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long term treatment with anti-tumor necrosis factor alpha therapy. Arthritis Rheum 2004;51:447-50.
19. Baecklund E, Ekbom A, Sparen P, et al. Disease activity and risk of lymphoma in patients with rheumatoid arthritis. Nested case-control study. BMJ 1998;317:180-1.
20. Wolfe F, Michaud MS. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-TNF therapy in 18,572 patients. Arthritis Rheum 2004;52:1740-51.
21. Symmons DPM, Silman AJ. Anti-tumor necrosis factor therapy and the risk of lymphoma in rheumatoid arthritis: No clear answer. Arthritis Rheum 2004;50:1703-6.
22. Gridley G, McLaughlin JK, Ekbom A, et al. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 1993;85:307-11.
23. Mellemkjaer L, Linet MS, Gridley G, Frisch M, Moller H, Olsen JH. Rheumatoid arthritis and cancer risk. Eur J Cancer 1996;32:1753-7.
24. Isomaki HA, Hakulinen T, Joutsenlahti U. Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis. J Chron Dis 1978;31:691-6.
25. Matteson EL, Hickey AR, Maguire L, Tilson HH, Urowitz MB. Occurrence of neoplasia in patients with rheumatoid arthritis enrolled in a DMARD Registry. Rheumatoid Arthritis Azathioprine Registry Steering Committee. J Rheumatol 1991;18:809-14.
26. Ekstrom K, Hjalgrim H, Brandt L, et al. Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives. Arthritis Rheum 2003;48:963-70.